9,457 Shares in Ligand Pharmaceuticals Incorporated $LGND Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. acquired a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 9,457 shares of the biotechnology company’s stock, valued at approximately $2,954,000.

Other institutional investors also recently bought and sold shares of the company. Ranger Investment Management L.P. bought a new stake in Ligand Pharmaceuticals during the 2nd quarter valued at $81,424,000. Bank of New York Mellon Corp purchased a new position in shares of Ligand Pharmaceuticals in the 2nd quarter valued at $41,429,000. William Blair Investment Management LLC bought a new position in shares of Ligand Pharmaceuticals in the 3rd quarter worth $37,264,000. Russell Investments Group Ltd. raised its position in shares of Ligand Pharmaceuticals by 41.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 170,089 shares of the biotechnology company’s stock worth $53,131,000 after acquiring an additional 49,785 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Ligand Pharmaceuticals by 31.4% in the 1st quarter. Bank of America Corp DE now owns 157,865 shares of the biotechnology company’s stock worth $31,518,000 after acquiring an additional 37,696 shares in the last quarter. 91.28% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Ligand Pharmaceuticals

In other news, Director Martine Zimmermann sold 2,000 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $318.17, for a total transaction of $636,340.00. Following the sale, the director directly owned 1,782 shares of the company’s stock, valued at $566,978.94. The trade was a 52.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jason Aryeh sold 3,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $320.05, for a total value of $960,150.00. Following the completion of the transaction, the director directly owned 105,476 shares in the company, valued at approximately $33,757,593.80. The trade was a 2.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 24,093 shares of company stock valued at $7,384,287. 5.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

LGND has been the subject of a number of analyst reports. Leerink Partners started coverage on Ligand Pharmaceuticals in a research note on Friday, August 14th. They set an “outperform” rating and a $330.00 price objective for the company. Citigroup boosted their target price on shares of Ligand Pharmaceuticals from $397.00 to $402.00 and gave the stock a “buy” rating in a report on Thursday, November 5th. Barclays boosted their target price on shares of Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, November 11th. HC Wainwright reissued a “buy” rating and set a $358.00 price target on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Finally, Royal Bank Of Canada raised their price target on shares of Ligand Pharmaceuticals from $345.00 to $357.00 and gave the company an “outperform” rating in a report on Friday, October 30th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $355.38.

Check Out Our Latest Stock Analysis on LGND

Ligand Pharmaceuticals Stock Performance

LGND opened at $286.87 on Friday. The company has a market cap of $5.74 billion, a P/E ratio of 128.07, a price-to-earnings-growth ratio of 5.27 and a beta of 1.16. The company has a quick ratio of 1.19, a current ratio of 1.22 and a debt-to-equity ratio of 0.71. The firm’s 50-day moving average price is $302.35 and its 200-day moving average price is $260.49. Ligand Pharmaceuticals Incorporated has a 52-week low of $175.89 and a 52-week high of $326.63.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last released its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share for the quarter, topping the consensus estimate of $2.33 by $0.34. The company had revenue of $78.75 million for the quarter, compared to the consensus estimate of $77.00 million. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. Ligand Pharmaceuticals’s revenue was down 31.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.09 EPS. As a group, equities analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current fiscal year.

Ligand Pharmaceuticals Profile

(Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

See Also

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.